They have the studied potency of the bivalent chimeric antigen receptor (CAR) T-cells which targets both epidermal growth factor receptor (EGFR) and interleukin-13 receptor alpha 2 (IL13Rα2) in recurrent glioblastoma and found a significant tumor size reduction and cytokine release indicating it’s promising activity in early efficacy. This evidence concerns the gene EGFR and glioblastoma.